

Dinuclear ruthenium(II) antimicrobial agents that selectively target polysomes *in vivo*Cite this: *Chem. Sci.*, 2014, 5, 685Fangfei Li,^a Elizabeth J. Harry,^b Amy L. Bottomley,^b Michael D. Edstein,^c Geoffrey W. Birrell,^c Clifford E. Woodward,^a F. Richard Keene^{*def} and J. Grant Collins^{*a}

Wide-field fluorescence microscopy at high magnification was used to study the intracellular binding site of Rubb₁₆ in *Escherichia coli*. Upon incubation of *E. coli* cells at the minimum inhibitory concentration, Rubb₁₆ localised at ribosomes with no significant DNA binding observed. Furthermore, Rubb₁₆ condensed the ribosomes when they existed as polysomes. It is postulated that the condensation of polysomes would halt protein production, and thereby inhibit bacterial growth. The results of this study indicate that the family of inert dinuclear ruthenium complexes Rubb_n selectively target RNA over DNA *in vivo*. Selective RNA targeting could be advantageous for the development of therapeutic agents, and because of differences in ribosome structure between bacteria and eukaryotic cells, the Rubb_n complexes could be selectively toxic to bacteria. In support of this hypothesis, the toxicity of Rubb₁₆ was found to be significantly less to liver and kidney cell lines than against a range of bacteria.

Received 2nd August 2013
Accepted 15th November 2013

DOI: 10.1039/c3sc52166d

www.rsc.org/chemicalscience

Introduction

There has been significant interest in the biological properties of inert ruthenium(II) complexes that contain polypyridyl ligands, primarily due to their nucleic acid binding ability.^{1–6} More recently, research has focused on the anticancer activity of these complexes and the site(s) of accumulation of the ruthenium complexes within eukaryotic cells.^{7–14} In addition to the studies with eukaryotic cells, there has also been considerable interest in the antimicrobial properties of inert polypyridylruthenium(II) complexes.^{15–19} As with eukaryotic cells, DNA binding is generally suggested or implied as the possible intra-cellular target. Indeed, in the only intra-bacterial localisation study reported to date (to our knowledge), Gill *et al.* showed that the rigidly-linked dinuclear ruthenium(II) complex [(phen)₂Ru-(μ-tpphz)-Ru(phen)₂]⁴⁺ (phen = 1,10-phenanthroline; tpphz = tetrapyrrodo [3,2-a:2',3'-c:3'',2''-h:2''',3'''-j] phenazine) bound chromosomal DNA in *Staphylococcus aureus*.⁹

However, toxicity has always been the major concern for the DNA-targeting metal complexes. Due to the lack of variation in the structure of DNA between bacteria and eukaryotic cells, DNA is unlikely to provide the selectivity required for development of a clinically-useful antimicrobial drug. By contrast, ribosomal RNA (rRNA), the most abundant form of RNA in both eukaryotes and bacteria,^{20,21} is an essential component of ribosomes which exhibit significant differences in bacteria and eukaryotic cells.²² While many antimicrobial drugs in current clinical use target bacterial ribosomes, few if any directly target bacterial chromosomal DNA without causing severe toxicity and side effects.^{23–25} Therefore, RNA binding could be advantageous for the development of metal complexes as new antimicrobial agents.

We have recently demonstrated that a series of dinuclear ruthenium(II) complexes which contain a flexible methylene chain in the bridge [{Ru(phen)₂}₂(μ-bb_n)]⁴⁺ {“Rubb_n”, where bb_n = bis[4(4'-methyl-2,2'-bipyridyl)]-1,*n*-alkane – see Fig. 1} exhibit




Fig. 1 The structure of the dinuclear polypyridylruthenium(II) complexes Rubb_n, where *n* = 2, 5, 7, 10, 12 and 16.

^aSchool of Physical, Environmental and Mathematical Sciences, University of New South Wales, Australian Defence Force Academy, Canberra, ACT 2600, Australia. E-mail: g.collins@adfa.edu.au

^bThe ithree institute, University of Technology Sydney, PO Box 123, Broadway, NSW 2007, Australia

^cDepartment of Drug Evaluation, Australian Army Malaria Institute, Gallipoli Barracks, Enoggera, QLD 4051, Australia

^dCentre for Biodiscovery and Molecular Development of Therapeutics, James Cook University, Townsville, QLD 4811, Australia

^eSchool of Pharmacy and Molecular Sciences, James Cook University, Townsville, QLD 4811, Australia. E-mail: richard.keene@jcu.edu.au

^fSchool of Chemistry and Physics, University of Adelaide, Adelaide, SA 5066, Australia

excellent antimicrobial activity against both Gram positive and Gram negative bacteria, and retain their activity against drug-resistant strains such as methicillin-resistant *S. aureus* (MRSA).^{17–19} Similarly to other dinuclear inert ruthenium(II) complexes that contain polypyridyl ligands, the Rubb_n complexes bind DNA and RNA relatively strongly *in vitro*.^{26–28} However, the Rubb_n complexes show a distinct preference for non-duplex structures, e.g. bulges and hairpin loops.^{27,28} RNA contains a larger proportion of non-duplex type structures than DNA, forming complicated three-dimensional structures comprising of loops, bulges, pseudo-knots and turns.⁵ Consequently, we postulated that the Rubb_n complexes would preferentially bind RNA, rather than DNA, in bacterial cells and could have significant clinical potential as novel antimicrobial agents with good selectivity and low toxicity.

Among the Rubb_n compounds, Rubb₁₆ has shown the best antimicrobial activity against bacteria with the most rapid and efficient cellular uptake.¹⁸ In one of our earlier studies, confocal microscopy was used to examine *Escherichia coli* that had been incubated with Rubb₁₆.¹⁸ Although the magnification and resolution was relatively low, the results suggested that the ruthenium complex localised within the bacterium, but in a manner that was not consistent with chromosomal DNA binding. Consequently, in the present study we aimed to determine the intracellular binding site of Rubb₁₆ by wide-field fluorescence microscopy at high magnification. The results indicate that Rubb₁₆ localises at ribosomes in *E. coli*, selectively binding RNA of ribosomes, most likely as 70S ribosome and polysomes. It is the first time that a synthetic metal complex (not including metal-based derivatives of existing antibiotics) has shown *in vivo* RNA binding activity in bacteria, with the ribosome/polysome localisation being visualised *via* fluorescence microscopy. The cytotoxicity of Rubb₁₆ against liver and kidney cells (where drugs usually accumulate) was also investigated, and the results provide evidence of the selectivity of Rubb₁₆ for bacterial cells over eukaryotic cells.

Experimental

Materials

Rubb₁₆ was synthesised as described previously.²⁹ Luria Broth base was purchased from BD Difco. SYTO 9 Green fluorescent nucleic acid stain and the DNA stain DAPI (4',6-diamidino-2-phenylindole) were obtained from Molecular Probes, Invitrogen. Rifampicin and chloramphenicol were purchased from Sigma-Aldrich.

Bacterial strains and growth conditions

E. coli MG1665 was used in this study. The bacterial strain was grown on Luria Broth (LB) agar plates at 37 °C. A bacterial culture was obtained by inoculating bacteria in LB media and incubating overnight in a shaking incubator in a water bath at 37 °C. The overnight culture was then diluted to a suspension with an optical density of approximately 0.05 at 600 nm (OD₆₀₀). A bacterial log-phase culture was obtained by continuing the incubation of this suspension for approximately 2 h until the OD₆₀₀ reached 0.5.

MIC assay

The minimum inhibitory concentration (MIC) was determined by the broth microdilution method as outlined in the CLSI guidelines.³⁰ The overnight bacterial culture was diluted to a concentration of $4-8 \times 10^5$ cfu mL⁻¹. Rubb₁₆ was serially diluted in LB media on a sterile 96-well plate with a final volume of 100 µL. The bacterial suspension (100 µL) was added to each well and the final concentration range of Rubb₁₆ ranged from 0.125 to 128 µg mL⁻¹. The plate was then placed in a static incubator at 37 °C for 14–16 h before the MIC results were read.

Drug treatment and staining protocols

A Rubb₁₆ stock solution was prepared in Milli-Q water at a concentration of 128 µg mL⁻¹. In the time-course movie and SYTO 9 competition experiments, the log-phase bacterial culture was added to Rubb₁₆ at MIC and incubated for 1 h. For the other assays, the incubation time was 15 min and the concentration of Rubb₁₆ ranged from MIC to 4× MIC as described. After incubation with Rubb₁₆, the cells were washed twice with phosphate buffer solution before further treatment or preparation for slides.

The concentrations of SYTO 9 and DAPI used in the co-localisation assays were 1 µM and 20 µg mL⁻¹, respectively. The *E. coli* cells were incubated at room temperature for 15–30 min before being loaded onto agarose pads on slides for microscopy.

Rifampicin and chloramphenicol were initially dissolved in 20 µL of ethanol and then diluted in Milli-Q water to a concentration of 2 mg mL⁻¹ and 20 mg mL⁻¹, respectively. Bacterial cells in the log phase of growth were treated with either of the inhibitors at a concentration of 128 µg mL⁻¹ for 30 min before Rubb₁₆ was added.

Live cell microscopy

All live cell microscopy was performed by placing cells on 2% (w/v) agarose pads (prepared with identical media to that in which the cells were grown) within a 65 µL Gene Frame (Thermo Fisher Scientific). Time-course movies and luminescent images were obtained using a Zeiss Axioplan 2 fluorescence microscope (Carl Zeiss) as described previously.^{31,32} SYTO 9 and DAPI fluorescence and Rubb₁₆ phosphorescence were visualised with filter sets 488009, 02 and 488015 (Carl Zeiss), respectively. Time-lapse studies were performed using a Zeiss Axioplan 2 fluorescence microscope with a Zeiss heated stage equipped with an objective heater, heatable universal mounting frame and an achromatic condenser, set at 37 °C. The movie was set for 20 min at 2 min intervals with an exposure time of 200 ms. Images were analysed and processed using AxioVision version 4.5 (Carl Zeiss).

Rubb₁₆ phosphorescence quenching by SYTO 9 and rifampicin

The effect of SYTO 9 or rifampicin on the Rubb₁₆ phosphorescence was determined by monitoring the Rubb₁₆ emission upon addition of SYTO 9 (0.03–4 µM) or rifampicin (0.125–512 µg mL⁻¹) to a Rubb₁₆ solution at constant concentration (4 µg mL⁻¹; final volume of 200 µL).



Cytotoxicity of Rubb₁₂ and Rubb₁₆ in mammalian cell lines

The *in vitro* cytotoxicity of Rubb₁₆ was assessed against the BHK (baby hamster kidney) cell line and two human cell lines – HEK-293 (embryonic kidney) and HEP-G2 (liver carcinoma) – using the alamar Blue cytotoxicity assay.³³

Results

Localisation of Rubb₁₆

The MIC of Rubb₁₆ against *E. coli* MG1665 was determined to be 4 $\mu\text{g mL}^{-1}$. An initial microscopy experiment was carried out to confirm the effect of Rubb₁₆ at MIC on the growth of the bacteria. *E. coli* cells were incubated with Rubb₁₆ at 37 °C for 1 hour. The treated cells were then prepared and imaged using time-lapse fluorescence microscopy over a 20 minute time-course. During the movie, no elongation of the bacteria was observed in Rubb₁₆-treated samples while untreated control bacteria exhibited normal elongation, confirming that Rubb₁₆ inhibited the growth of the bacteria at MIC (data not shown).

E. coli cells were then incubated with Rubb₁₆ at MIC (4 $\mu\text{g mL}^{-1}$), 2 \times MIC (8 $\mu\text{g mL}^{-1}$) and 4 \times MIC (16 $\mu\text{g mL}^{-1}$) at 37 °C for 1 hour, washed twice and loaded on agarose pads on slides for fluorescence microscopy. The phase-contrast and luminescence images are shown in Fig. 2. At MIC, orange phosphorescent “spots” indicate that Rubb₁₆ predominantly accumulated at the cell poles and in the middle of the cell at the cylindrical wall. Each of the Rubb₁₆ spots is approximately 0.3 μm (3000 Å) in diameter, and interestingly, the spots located at the cell poles appear to be at the point of maximum curvature. This localisation pattern was also observed at 2 \times and 4 \times MIC, but with additional spots in most cells (data not shown). Previous NMR studies have shown that the Rubb_n family of complexes bind strongly to both DNA and RNA.^{26–28} For example, Rubb_n complexes bind chromosomal DNA in *S. aureus* cells (albeit rather weakly).²⁸ However, the localisation of Rubb₁₆ shown in Fig. 2 suggests that the major accumulation site is not chromosomal DNA, which generally occupies a central region of a non-dividing *E. coli* cell with the poles generally devoid of DNA.³⁴ The DNA-“selective” dye DAPI (which binds DNA

100-fold more strongly than RNA and has a 3-fold higher fluorescence quantum yield when bound to DNA than to RNA) was used to track the DNA distribution in *E. coli* cells.³⁵

Co-staining with DAPI

DAPI-stained *E. coli* cells that had been previously treated with Rubb₁₆ are shown in Fig. 3. The localisation pattern of Rubb₁₆ is consistent with that in bacteria without DAPI staining. At MIC, two to three relatively faint Rubb₁₆ phosphorescence spots are observed and the nucleoid appears to occupy the rest of the cell. Alternatively, five to six spots are observed at 4 \times MIC and the nucleoid appears to have condensed and become strand-like in appearance (see Fig. 3). At both MIC and 4 \times MIC there was no significant overlap of DAPI and Rubb₁₆ luminescence, suggesting that chromosomal DNA is not the major localisation site for Rubb₁₆.

Competition assay with SYTO 9

Given that Rubb₁₆ has a high affinity for nucleic acids, the lack of Rubb₁₆ phosphorescence localised at chromosomal DNA suggests that RNA is the major *in vivo* binding target for Rubb₁₆. SYTO 9 is a fluorescent dye that binds RNA more strongly than DNA (although it has a higher fluorescence quantum yield when bound to DNA). Gill *et al.* have utilised SYTO 9 to visualise RNA in the nucleolus of eukaryotic cells.⁹ SYTO 9 was used in the present study to further investigate the localisation of Rubb₁₆ with respect to the nucleic acid-enriched regions of the bacteria.

E. coli cells at the mid-log phase of growth were incubated with Rubb₁₆ at MIC for 1 hour and then stained with SYTO 9. After 15 minutes of exposure to SYTO 9, the Rubb₁₆ phosphorescence decreased significantly (shown in Fig. 4). After 30 minutes, no Rubb₁₆ phosphorescence was observed. In control experiments, it was shown that SYTO 9 does not quench the Rubb₁₆ phosphorescence, even at concentrations four-times higher than that used in experiments where no Rubb₁₆ phosphorescence was observed. Instead, SYTO 9 appears to be displacing Rubb₁₆ from its binding site.

The effect of chloramphenicol and rifampicin on Rubb₁₆ localisation

The DAPI co-localisation assays indicated that DNA is not the major target, while the competitive binding with SYTO 9 suggests binding of Rubb₁₆ to RNA in the cytoplasm. The polar and central localisation of the Rubb₁₆ foci at MIC are within the regions of *E. coli* cells normally occupied by ribosomes.^{36,37} This suggests that rRNA within the ribosomes may be a primary binding target for Rubb₁₆, although the volume of the foci may appear to be too small to account for all the ribosomes in the cell. Therefore we conducted further localisation studies of Rubb₁₆ in *E. coli*, wherein the population and cellular distribution of RNA and ribosomes were intentionally disrupted by the use of antibiotics.

It has been reported that antibiotics which inhibit either transcription or translation can affect the morphology and distribution of the nucleoid as well as the population of RNAs and ribosomes in bacterial cells.^{36–38} Chloramphenicol and




Fig. 2 Rubb₁₆ localisation in *E. coli* MG1665 cells at MIC – 4 $\mu\text{g mL}^{-1}$. The fluorescence microscopy images are: (a), phase-contrast; (b), phosphorescence; and (c), merged. Scale bar = 5 μm .






Fig. 3 Fluorescence microscopy photos of *E. coli* MG1665 cells at their mid-log phase of growth incubated with Rubb₁₆ at MIC (a–d) and 4 × MIC (e–h) for 1 hour and then stained with DAPI (coloured green for greater contrast). Phase-contrast (a and e); fluorescence – DAPI (b and f); phosphorescence – Rubb₁₆ (c and g); merged DAPI and Rubb₁₆ (d and h). Scale bar = 2 μm.




Fig. 4 Fluorescence microscopy photos of *E. coli* MG1665 cells at their mid-log phase incubated with Rubb₁₆ at MIC (4 μg mL^{−1}) for 1 hour and then stained with SYTO 9 for 15 minutes. The arrows indicate the remaining Rubb₁₆ phosphorescence. (a), Phase-contrast; (b), fluorescence – SYTO 9; (c), phosphorescence – Rubb₁₆; (d), merged SYTO 9 and Rubb₁₆. Scale bar = 2 μm.

rifampicin are two antibiotics that have been commonly used to bring about such effects. Chloramphenicol inhibits translation by binding to the bacterial ribosome and preventing protein chain elongation *via* the inhibition of peptidyl transferase.^{36,37} On the other hand, rifampicin halts transcription initiation by inhibiting RNA polymerase (RNAP).³⁷ It has been previously shown that when exponentially-growing *E. coli* cells are treated with chloramphenicol, the nucleoids become more condensed both radially and axially. Subsequently, the ribosomes then expand to fill the space made available by the nucleoid contraction.^{36,37} On the other hand, it has been established that

in bacterial cells treated with rifampicin (for incubation times ≥ 30 minutes), the nucleoid material expands so that it is distributed throughout the entire cell.^{37,38} It was also shown that the ribosomes become distributed throughout the cellular space, rather than being localised at the polar regions.

Using the same experimental conditions as Bakshi *et al.*,³⁷ *E. coli* cells treated with 128 μg mL^{−1} chloramphenicol for 30 minutes were then incubated with Rubb₁₆ at MIC for 15 minutes. After chloramphenicol treatment, the DAPI-stained nucleoid contracted, while the Rubb₁₆ luminescence was mainly located at the two cell end-caps (Fig. 5a–d). In comparison with chloramphenicol-untreated bacteria (shown again for convenience in Fig. 5e–g), the Rubb₁₆ phosphorescence in the chloramphenicol-treated cells displayed no bright foci but was instead more uniform in intensity, and occupied most of the end-cap volumes. Indeed, the Rubb₁₆ distribution was entirely consistent with that of ribosomes in chloramphenicol-treated cells observed in previous studies.³⁷ This strongly suggests that Rubb₁₆ co-localises with the rRNA in the ribosomes of these cells.

E. coli cells were also treated with 128 μg mL^{−1} rifampicin for 30 minutes³⁷ and then incubated with Rubb₁₆ at MIC for 15 minutes. As with previous studies, we noted that the nucleoid in rifampicin-treated cells expanded to fill the entire cell (Fig. 6b). Surprisingly, no phosphorescence of Rubb₁₆ was subsequently observed. In control experiments, it was shown that rifampicin only quenches the Rubb₁₆ phosphorescence by 30% at 128 μg mL^{−1}. Consequently, it is probable that the ribosome-bound Rubb₁₆ was now dispersed evenly throughout the whole cell region and the weak phosphorescence of Rubb₁₆ was beyond the detection limit of the fluorescence microscope. Hence, the incubation concentration of Rubb₁₆ was boosted to 4 × MIC; however, once again no phosphorescence was detected (Fig. 6). A second control experiment was conducted whereby *E. coli* cells were incubated with Rubb₁₆ at 4 × MIC for 15 minutes before the addition of rifampicin. The results are shown in Fig. 7. Remarkably, the observed Rubb₁₆ phosphorescence was the same as if the cells had not been treated with






Fig. 5 Top row (a–d) – fluorescence microscopy photos of chloramphenicol-treated *E. coli* MG1665 cells incubated with Rubb₁₆ at MIC for 15 minutes and then stained with DAPI (coloured in green for contrast). (a), Phase-contrast; (b), fluorescence – DAPI; (c), phosphorescence – Rubb₁₆; (d), merged DAPI and Rubb₁₆. Bottom row (e–g) – the microscopy images of Rubb₁₆ localised in chloramphenicol-untreated *E. coli* cells at MIC. (e), Phase; (f), phosphorescence – Rubb₁₆; (g), merged. Scale bar = 2 μm.




Fig. 6 Fluorescence microscopy photos of rifampicin-treated *E. coli* MG1665 cells incubated with Rubb₁₆ at 4 × MIC for 15 min and then stained with DAPI. (a), Phase-contrast; (b), fluorescence – DAPI (coloured green for contrast); (c), phosphorescence – Rubb₁₆; (d), merged DAPI and Rubb₁₆. Scale bar = 2 μm.

rifampicin. Furthermore, the nucleoid also appeared to be condensed and essentially identical to that in untreated cells.

Cytotoxicity assay

We have demonstrated that the Rubb_n complexes are significantly less toxic to red blood cells and a human leukaemia cell line than against bacteria in our earlier work.¹⁷ However, to further explore the potential selectivity of the Rubb_n complexes between bacteria and eukaryotic cells, we evaluated the cytotoxicity of Rubb₁₆ towards liver and kidney cell lines. Cell lines from these organs were selected because the liver and kidney are the major sites of drug metabolism.³⁹ The results are summarised in Table 1. The cytotoxicity of Rubb₁₆ was compared with its MICs against bacterial cell strains of (Gram positive) *S. aureus* and (Gram negative) *E. coli* shown as a selectivity index

(SI = IC₅₀/MIC). The IC₅₀ values of Rubb₁₆ against liver and kidney cells are significantly higher than the MICs against a range of pathogenic bacteria, including MRSA and *Pseudomonas*

Table 1 Cytotoxicity of Rubb₁₆ against three eukaryotic cell lines (IC₅₀) and the selectivity index (SI) against *S. aureus* ATCC 25923 (MIC determined in our previous study)¹⁷ and the *E. coli* MG1665 strain used in this study. SI is the ratio of IC₅₀ to MIC. The MIC of Rubb₁₆ against *S. aureus* and *E. coli* are 1 μg mL^{−1} (0.6 μM) and 4 μg mL^{−1} (2.5 μM) respectively. BHK = baby hamster kidney; HEK-293 = embryonic kidney; and HEP-G2 = liver carcinoma

	BHK	HEK-293	HEP-G2
IC ₅₀ (μM)	210 ± 60	172 ± 65	106 ± 29
SI (<i>S. aureus</i>)	350	287	177
SI (<i>E. coli</i>)	84	69	42




Fig. 7 Fluorescence microscopy images of *E. coli* MG1665 cells incubated with Rubb₁₆ at 4 × MIC for 15 minutes and then treated with rifampicin for 30 minutes and finally stained with DAPI. (a), Phase-contrast; (b), fluorescence – DAPI (coloured in green for contrast); (c), phosphorescence – Rubb₁₆; (d), merged DAPI and Rubb₁₆. Scale bar = 2 μm.



aeruginosa.¹⁷ It is noteworthy that Rubb₁₆ showed a better selectivity to Gram positive bacteria than their Gram negative counterparts.

Discussion

A bacterial ribosome consists of a small 30S subunit and a large 50S subunit, with both components comprised of rRNA and protein. These two subunits associate together with mRNA to form the intact 70S ribosome. A number of ribosomes attached to mRNA form an anionic polysome chain that can efficiently synthesise protein. It has been shown that around 80% of bacterial ribosomes are active in protein synthesis independent of growth rate and conditions.^{37,40} In growing bacterial cells, most of the active ribosomes occur in polysomes.^{41,42} A theoretical model of cellular organisation in *E. coli*, proposed by Mondal *et al.*, purports that ribosomes segregate to the cylindrical wall and polar regions of a bacterial cell to sample the space left unoccupied by the DNA in order to maximise their translational entropy.⁴³

Treating *E. coli* cells with Rubb₁₆ (at MIC) gave rise to small bright foci in regions where polysomes are expected to be located (Fig 2 and Fig. 5e–g). In experiments where the *E. coli* cells were pre-treated with chloramphenicol no bright foci were observed, instead a more uniform and diffuse Rubb₁₆ phosphorescence filled the end cap regions not occupied by the nucleoid. This suggests that Rubb₁₆ is bound to the rRNA in the polysomes of these cells. It could be expected that the binding of Rubb₁₆ would be similar in cells untreated by chloramphenicol. However, the Rubb₁₆ phosphorescent foci in untreated cells at MIC do not appear to have sufficient volume to account for the number of ribosomes in a typical cell. This paradox can be explained by the occurrence of polysome aggregation. Precipitation of polysomes with multivalent cations (*e.g.* Cu²⁺, Zn²⁺ and Ca²⁺) is a well-known phenomenon⁴⁴ and provides a plausible explanation for the findings in this study. An estimate of the total volume of the small foci at MIC indicates that they represent 30–50% of the ribosomes.⁴⁵ Hence we suggest that when untreated *E. coli* cells are exposed to Rubb₁₆ at MIC, a proportion (30–50%) of the ribosomes condense and the subsequent high concentration of Rubb₁₆ gives rise to intense luminescent foci, which dominate the image. The remaining non-aggregated polysomes give rise to a lower intensity luminescence. To confirm this, further image analysis of this system was performed to enhance the luminescence of the Rubb₁₆ outside of the foci. Fig. 8 shows that the foci are part of a greater volume of Rubb₁₆ phosphorescence, which has a lower intensity than the foci, but is still much greater than that of the nucleoid and the background solution. These regions of secondary intensity have a volume and location that is consistent with the expected distribution of non-aggregated polysomes. Treatment of *E. coli* with chloramphenicol is known to give rise to a reduction in the percentage of ribosomes that exist as polysomes.⁴² Furthermore, as noted earlier, chloramphenicol condenses the nucleoid and allows polysomes to expand into a greater volume, thus reducing their concentration. Taken together, this would lead to diminished polysome




Fig. 8 Rubb₁₆ localisation in *E. coli* MG1665 cells at MIC (left) and 2× MIC (right), with the image re-processed to enhance the luminescence of the Rubb₁₆ outside of the foci.

aggregation upon addition of Rubb₁₆. Indeed it appears that, when cells are treated with chloramphenicol, the polysomes remain largely dispersed in the cytoplasm, as indicated by the relatively uniform intensity of the Rubb₁₆ phosphorescence.

At higher concentrations (4× MIC) the ruthenium complex could also condense the chromosomal DNA, as shown by staining with DAPI. DNA condensation in the presence of multivalent cationic species is well established.⁴⁶ At 4× MIC of Rubb₁₆, the rapid and high uptake of Rubb₁₆ would allow some of the ruthenium complex to also bind at secondary lower affinity sites such as the chromosomal DNA. It was puzzling that no significant phosphorescence of the Rubb₁₆ was observed from the nucleoid region at the higher concentration of Rubb₁₆. It is likely that the Rubb₁₆ concentration in the nucleoid remained too low to be observed as a phosphorescence image, despite it causing contraction of the chromosomal DNA. Based upon the number of nucleic acid base pairs and the volume available, the charge density on chromosomal DNA in an *E. coli* bacterium is about 100-fold less than that of a 70S ribosome (without considering the negative charge of the proteins).⁴⁷ This is consistent with the relatively lower binding to chromosomal DNA that was previously observed with *S. aureus*.²⁸

It is noteworthy that at 4× MIC the Rubb₁₆ phosphorescence remained localised and did not expand into the available cellular volume despite nucleoid contraction. Instead, an increased number of localised spots appeared in each cell, compared with cells incubated with Rubb₁₆ at MIC (Fig. 3g and h). An estimate of the total volume of the foci in this case reveals that they could account for approximately 70–100% of the ribosomes. We also observed faint orange phosphorescence in the areas surrounding the condensed nucleoid (see Fig. 3g and h). This could indicate Rubb₁₆ binding to nascent RNA that was localised near the nucleoid before being incorporated into ribosomes.⁵¹

The accumulation of ribosomes into polysomal chains gives rise to a significant negative electrostatic potential, which strongly attracts the cationic Rubb₁₆. It is possible that electrostatic correlations cause polysome chains to collapse, *via* a mechanism similar to that which drives DNA condensation by multivalent cations.⁴⁶ Polysome aggregates would be expected to nucleate in regions where they have a high concentration. Furthermore, the negatively-charged inner membrane would be likely to provide a scaffold for nucleation due to cooperative adsorption. This explains why the bright foci tended to appear



bound to the membrane at the polar end caps, and in the equatorial regions for larger cells (wherein the nucleoid displays two lobes). Interestingly, fainter surface-bound spots were also observed within the cells, indicating areas where secondary nucleation had occurred. Over time, it is probable that these smaller aggregates will diminish through some coarsening mechanism, such as Ostwald ripening, to give rise to just a few major sites of aggregation.⁵²

Polysomes in the cytosol are degraded in a matter of minutes, but their population is replenished by mRNA formation through transcription in the nucleoid. Rifampicin halts transcription through inhibition of RNAP, which co-localises with chromosomal DNA. Therefore, rifampicin does not directly compete with Rubb₁₆ binding. Pre-treatment of *E. coli* cells with rifampicin led to no measurable detection of Rubb₁₆, even at 4× MIC. During the 30 minutes of rifampicin incubation before the addition of Rubb₁₆, the polysome population would have completely degraded and the 70S ribosomes dissociated into the free 30S and 50S subunits.^{37,42} These smaller particles are better able to mix with the nucleoid material and the latter is able to expand into the cell cavity. In this environment Rubb₁₆ would compete less effectively with higher concentrations of other cations to neutralise the ribosomal material. The higher mixing entropy and lower charge density favour a dispersed ribosomal phase relative to the aggregated one (even in the presence of Rubb₁₆). This leads to a negligible Rubb₁₆ phosphorescence intensity throughout the cell, due to the lack of ribosomal aggregation.

When rifampicin was added to cells previously incubated with 4× MIC Rubb₁₆, the polysome aggregates which initially formed remained intact, as indicated by the persistent bright foci. That is, the subsequent treatment with rifampicin did not lead to degradation of the polysomal aggregates. The implication is that the formation of condensed aggregates lends some protection to the polysomes from the natural degradation mechanisms in the cell. This was possibly due to large enzymatic molecules finding it difficult to penetrate into the aggregates. On the other hand, the nucleoid was also unaffected by the addition of rifampicin – that is, it did not expand into the cellular cavity, as was the case where rifampicin was added first. The retained compactness of the nucleoid may have been due to the stability of a nucleoid condensed by the addition of 4× MIC Rubb₁₆. Nucleoid compaction may have also negated the effect of the rifampicin on transcription, thus providing an alternative (or additional) cause for the continued presence of polysome aggregates.

Treatment of the cells with the dye SYTO 9, after incubation with Rubb₁₆, gave rise to a surprising diminution of the Rubb₁₆ phosphorescence (Fig. 4). Because of their chemical inertness, Rubb_n complexes bind non-duplex nucleic acid structures reversibly as minor groove binders *via* electrostatic interaction with the negative charge of the sugar phosphate backbone.^{27,28} As a small cationic dye that binds strongly to RNA *via* intercalation, SYTO 9 is likely to diffuse within the aggregates and slowly displace Rubb₁₆ from the ribosomes. Presumably the polysomal aggregates subsequently re-dissolve due to the decreasing concentration of bound Rubb₁₆. The dissociated

Rubb₁₆ then diffuses out through the cytoplasmic membrane, reducing its total concentration in the cytosol. While SYTO 9 appears to compete with Rubb₁₆ for binding sites on the ribosome, chloramphenicol does not displace the ruthenium complex. As SYTO 9 is a non-specific RNA binding agent, but chloramphenicol selectively binds at the 23S rRNA of the 50S subunit,⁵³ the results tentatively suggest Rubb₁₆ localises at the 30S ribosomal subunit.

We have previously demonstrated that the Rubb_n family of complexes are highly active antimicrobial agents. In this study we have also demonstrated that Rubb₁₆ was 40- to 350-fold less toxic to liver and kidney cells compared to several strains of bacteria, indicating a significant selective toxicity for bacteria over eukaryotic cells. In our earlier studies, we have shown that Rubb₁₆ accumulates primarily in the mitochondria in eukaryotes.¹⁰ It has been reported that antibiotics targeting the ribosome may show a certain degree of toxicity towards eukaryotes, such as aminoglycosides which cause ototoxicity and nephrotoxicity.⁵⁴ Although those antibiotics generally have no effect on the cytoplasmic ribosomes in eukaryotes, their toxicity is triggered by the inhibition of mitochondrial ribosomes (mitoribosomes).⁵⁴ Compared to cytoplasmic ribosomes, mitoribosomes are considered to be more similar to bacterial ribosomes and they contain some sequences that can bind ribosome-targeting antibiotics.⁵⁴ However, there are still considerable differences in the physical properties of mitochondrial 55S and bacterial 70S ribosomes: the latter contain around 65% RNA, whereas RNA only makes up 33% of the former.^{55,56} Moreover, 55S ribosomes have a larger mass and physical dimensions than their 70S bacterial counter-parts.⁵⁷ In addition, a high population of polysomes are found in bacteria while mitoribosomes only appear in mitopolysomes occasionally.^{41,58} All of these factors suggest that the absolute charge density in mitoribosomes is expected to be lower than that in bacterial ribosomes, which would result in a weaker binding affinity of Rubb₁₆. Finally, it has been estimated that in bacteria 15% of 70S ribosomes are membrane-associated.⁵⁹ By contrast, in mitochondria most 55S ribosomes are associated with the inner mitochondrial membrane.⁵⁸ Thus, although Rubb₁₆ accumulates in mitochondria in eukaryotes, mitoribosomes would be unlikely to be condensed by Rubb₁₆. This is especially so, given that the uptake of ruthenium complex in eukaryotes is much less and slower than that in bacteria.^{10,18} This hypothesis is consistent with the relatively low cytotoxicity against liver and kidney cells of Rubb₁₆ compared to its MIC values.

Conclusions

The results of this study show that Rubb₁₆ – a dinuclear polypyridylruthenium(II) complex which contains a flexible methylene chain in the bridge – known to bind non-duplex nucleic acid structures *in vitro*, preferentially binds bacterial RNA *in vivo* and accumulates in bacterial ribosomes. The specific targeting and condensation of the polysomes would enable Rubb₁₆ to halt translation, thus interrupting protein synthesis in actively growing bacterial cells. Rapidly growing bacteria are expected to contain a larger population of polysomes due to the increased



requirement of cellular proteins. More importantly, Rubb₁₆ has significant potential as a broad-spectrum antibiotic and is expected to be effective against drug-resistant strains – as has been shown.¹⁷ Since the antimicrobial action appears to be controlled by electrostatic interactions with negatively-charged intracellular structures that are essential to all bacteria, mutations are unlikely to combat its activity unless they reduce the cellular uptake. Notably, Rubb₁₆ showed selective toxicity against bacteria over eukaryotic cells, and it appears to result from its RNA binding and localisation in ribosomes with high negative charge density. Furthermore, the modular design and general ease with which the structure of the ruthenium complexes can be modified will facilitate the optimisation of the selective antimicrobial activity of these compounds.

Acknowledgements

We are grateful to the Australian Research Council for funding support and Fangfei Li thanks the China Scholarship Council for a PhD scholarship. FRK acknowledges the award of a Visiting Professorship from UNSW Canberra (ADFA). The opinions expressed are those of the authors and do not necessarily reflect those of the Australian Defence Force or any extant Australian Defence Force policy.

References

- 1 B. Nordén, P. Lincoln, B. Akerman and E. Tuite, *Met. Ions Biol. Syst.*, 1996, **33**, 177.
- 2 K. E. Erkkila, D. T. Odom and J. K. Barton, *Chem. Rev.*, 1999, **99**, 2777.
- 3 C. Metcalfe and J. A. Thomas, *Chem. Soc. Rev.*, 2003, **32**, 215.
- 4 B. M. Zeglis, V. C. Pierre and J. K. Barton, *Chem. Commun.*, 2007, 4565.
- 5 F. R. Keene, J. A. Smith and J. G. Collins, *Coord. Chem. Rev.*, 2009, **253**, 2021.
- 6 M. R. Gill and J. A. Thomas, *Chem. Soc. Rev.*, 2012, **41**, 3179.
- 7 C. A. Puckett, R. J. Ernst and J. K. Barton, *Dalton Trans.*, 2010, **39**, 1159.
- 8 C. A. Puckett and J. K. Barton, *Biochemistry*, 2008, **47**, 11711.
- 9 M. R. Gill, J. Garcia-Lara, S. J. Foster, C. Smythe, G. Battaglia and J. A. Thomas, *Nat. Chem.*, 2009, **1**, 662.
- 10 M. J. Pisani, P. D. Fromm, Y. Mulyana, R. J. Clarke, H. Korner, K. Heimann, J. G. Collins and F. R. Keene, *ChemMedChem*, 2011, **6**, 848.
- 11 M. Matson, F. R. Svensson, B. Nordén and P. Lincoln, *J. Phys. Chem. B*, 2011, **115**, 1706.
- 12 F. R. Svensson, J. Andersson, H. L. Åmand and P. Lincoln, *J. Biol. Inorg. Chem.*, 2012, **17**, 565.
- 13 T. Chen, Y. Liu, W.-J. Zheng, J. Liu and Y.-S. Wong, *Inorg. Chem.*, 2010, **49**, 6366.
- 14 M. R. Gill, H. Derratt, C. G. W. Smythe, G. Battaglia and J. A. Thomas, *ChemBioChem*, 2011, **12**, 877.
- 15 F. P. Dwyer, E. C. Gyrfas, W. P. Rogers and J. H. Koch, *Nature*, 1952, **170**, 190.
- 16 F. P. Dwyer, I. K. Reid, A. Shulman, G. M. Laycock and S. Dixon, *Aust. J. Exp. Biol. Med. Sci.*, 1969, **47**, 203.
- 17 F. Li, Y. Mulyana, M. Feterl, J. M. Warner, J. G. Collins and F. R. Keene, *Dalton Trans.*, 2011, **40**, 5032.
- 18 F. Li, M. Feterl, Y. Mulyana, J. M. Warner, J. G. Collins and F. R. Keene, *J. Antimicrob. Chemother.*, 2012, **67**, 2686.
- 19 M. Pandrala, F. Li, M. Feterl, Y. Mulyana, J. M. Warner, L. Wallace, F. R. Keene and J. G. Collins, *Dalton Trans.*, 2013, **42**, 4686.
- 20 C. Peano, A. Pietrelli, C. Consolandi, E. Rossi, L. Petiti, L. Tagliabue, G. D. Bellis and P. Landini, *Microb. Inf. Exp.*, 2013, **3**, 1.
- 21 H. Lodish, A. Berk, S. L. Zipursky, P. Matsudaira, D. Baltimore and J. Darnell, *Molecular Cell Biology*, W. H. Freeman, New York, 4th edn, 2000.
- 22 S. Klinge, F. Voigts-Hoffmann, M. Leibundgut and N. Ban, *Trends Biochem. Sci.*, 2012, **37**, 189.
- 23 J. Poehlsgaard and S. Douthwaite, *Nat. Rev. Microbiol.*, 2005, **3**, 870.
- 24 T. Lambert, *Rev. sci. tech. Off. int. epiz.*, 2012, **31**, 57.
- 25 L. Ming, *Med. Res. Rev.*, 2003, **23**, 697.
- 26 C. B. Spillane, J. A. Smith, D. P. Buck, J. G. Collins and F. R. Keene, *Dalton Trans.*, 2007, 5290.
- 27 D. P. Buck, J. A. Paul, M. Pisani, J. G. Collins and F. R. Keene, *Aust. J. Chem.*, 2010, **63**, 1365.
- 28 F. Li, D. K. Weber, J. L. Morgan, J. G. Collins and F. R. Keene, *Dalton Trans.*, 2012, **41**, 6528.
- 29 Y. Mulyana, D. K. Weber, D. P. Buck, C. A. Motti, J. G. Collins and F. R. Keene, *Dalton Trans.*, 2011, **40**, 1510.
- 30 P. A. Wayne and Clinical and Laboratory Standards Institute, *Performance Standards for Antimicrobial Susceptibility Testing: Nineteenth Informational Supplement M100–S19*, C.L.S.I., USA, 2009.
- 31 P. C. Peters, M. D. Migocki, C. Thoni and E. J. Harry, *Mol. Microbiol.*, 2007, **64**, 487.
- 32 S. Moriya, R. A. Rashid, C. D. Andrade Rodrigues and E. J. Harry, *Mol. Microbiol.*, 2010, **76**, 634.
- 33 J. O'Brien, I. Wilson, T. Orton and F. Pognan, *Eur. J. Biochem.*, 2000, **267**, 5421.
- 34 E. Harry, L. Monahan and L. Thompson, *Int. Rev. Cytol.*, 2006, **253**, 27.
- 35 F. A. Tanious, J. M. Veal, H. Buczak, L. S. Ratmeyer and W. D. Wilson, *Biochemistry*, 1992, **31**, 3103.
- 36 J. Mascarenhas, M. H. W. Weber and P. L. Graumann, *EMBO Rep.*, 2001, **2**, 685.
- 37 S. Bakshi, A. Siryaporn, M. Goulian and J. C. Weisshaar, *Mol. Microbiol.*, 2012, **85**, 21.
- 38 J. E. Cabrera, C. Cagliero, S. Quan, C. L. Squires and D. J. Jin, *J. Bacteriol.*, 2009, **191**, 4180.
- 39 H. L. Liston, J. S. Markowitz and C. L. DeVane, *J. Clin. Psychopharmacol.*, 2001, **21**, 500.
- 40 H. Bremer and P. P. Dennis, in *Escherichia coli and Salmonella: Cellular and Molecular Biology*, ASM Press, Washington DC, 2nd edn, 1996, pp. 1553–1569.
- 41 L. A. Phillips and R. M. Franklin, *Cold Spring Harbor Symp. Quant. Biol.*, 1969, **34**, 243.
- 42 H. L. Ennis, *Antimicrob. Agents Chemother.*, 1972, **1**, 197.
- 43 J. Mondal, B. P. Bratton, Y. Li, A. Yethiraj and J. C. Weisshaar, *Biophys. J.*, 2011, **100**, 2605.



- 44 A. O. Jackson and B. A. Larkins, *Plant Physiol.*, 1976, **57**, 5.
- 45 These calculations are based upon the radius of a 70S ribosome being 10 nm, and hence have an approximate volume of $3.14 \times 10^3 \text{ nm}^3$. As there are approximately 20 000 ribosomes in a single *E. coli* cell (<http://www.bscb.org/?url=softcell/ribo>), the total volume of all the ribosomes would be around $0.06 \mu\text{m}^3$. Given the diameter of a single Rubb₁₆ phosphorescent spot is 0.3 μm , the volume of a single condensation spot is approximately $0.01 \mu\text{m}^3$.
- 46 V. B. Teif and K. Bohinc, *Prog. Biophys. Mol. Biol.*, 2011, **105**, 208.
- 47 The chromosomal DNA in an *E. coli* bacterium has a compact volume of $\sim 1 \mu\text{m}^3$ and contains 4.6×10^6 base pairs.⁴⁸ Therefore the nucleic acid density (DNA) at the nucleoid region of *E. coli* is nearly 10^7 nucleotides per μm^3 . The volume of an *E. coli* 70S ribosome is $3.4 \times 10^6 \text{ \AA}^3$, which contains 4560 nucleotides.^{49,50} Consequently the nucleic acid density (RNA) at a single 70S ribosome in *E. coli* is about 10^9 nucleotides per μm^3 .
- 48 T. Romantsov, I. Fishov and O. Krichevsky, *Biophys. J.*, 2007, **92**, 2875.
- 49 J. Zhu, *J. Struct. Biol.*, 1997, **118**, 197.
- 50 B. Alberts, A. Johnson, J. Lewis, M. Raff, K. Roberts and P. Walter, *Molecular Biology of the Cell*, Garland Science, New York, 4th edn, 2002.
- 51 D. J. Jin, C. Cagliero and Y. N. Zhou, *Chem. Rev.*, 2013, **113**, 8662.
- 52 W. Ostwald, *Zeitschrift für Physikalische Chemie*, 1897, **22**, 289.
- 53 L. McCoy, Y. Xie and Y. Tor, *Wiley Interdiscip. Rev.: RNA*, 2011, **2**, 209.
- 54 E. C. Bottger, *Cell. Mol. Life Sci.*, 2007, **64**, 791.
- 55 E. C. Koc, W. Burkhardt, K. Blackburn, M. B. Moyer, D. M. Schlatter, A. Moseley and L. L. Spemulli, *J. Biol. Chem.*, 2001, **276**, 43958.
- 56 D. Ridgway, G. Broderick, A. Lopez-Campistrous, M. Ru'aini, P. Winter, M. Hamilton, P. Boulanger, A. Kovalenko and M. J. Ellison, *Biophys. J.*, 2008, **94**, 3748.
- 57 M. G. Hamilton and T. W. O'Brien, *Biochemistry*, 1974, **13**, 5400.
- 58 J. J. Curgy, *Biol. Cell*, 1985, **54**, 1.
- 59 J. O. Ortiz, F. Forster, J. Kurner, A. A. Linaroudis and W. Baumeister, *J. Struct. Biol.*, 2006, **156**, 334.

